Last reviewed · How we verify
NCT05672966
Phase I Clinical Trial of a Candidate HPV Vaccine
Phase 1 trial testing Human papillomavirus (HPV) Vaccine in Human Papillomavirus Infection in 40 participants. Status unknown.
31 July 2024
Quick facts
| Lead sponsor | Wuhan BravoVax Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 40 |
| Start date | 1 August 2023 |
| Primary completion | 31 July 2024 |
| Estimated completion | 31 October 2024 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Human papillomavirus (HPV) Vaccine — full drug profile →
- Placebo
Conditions studied
- Human Papillomavirus Infection — all drugs for Human Papillomavirus Infection →
Sponsor
Wuhan BravoVax Co., Ltd. — full company profile →
Who can join
Adults 18 to 35, any sex, with Human Papillomavirus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase I, first-in-human, randomized, observer-blinded, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and immunogenicity of BV601 (a HPV Vaccine) in healthy adult volunteers.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Vaccination with a Human Papillomavirus L2 Multimer Provides Broad Protection against 17 Human Papillomavirus Types in the Mouse Cervicovaginal Challenge Model.
Han Z, Wang S, Mu T, Zhao P, et al · · 2024 · cited 1× · PMID 38932417 · DOI 10.3390/vaccines12060689
Verify or expand the search:
- PubMed search for NCT05672966
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Human Papillomavirus Infection
Currently open trials in the same condition.
- NCT07281430 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) · NA · recruiting
- NCT06598475 — Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve · NA · recruiting
- NCT06611553 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02) · NA · active not recruiting
- NCT06611540 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03) · NA · active not recruiting
- NCT06498661 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) · NA · recruiting
Other Wuhan BravoVax Co., Ltd. trials
Trials by the same sponsor.
- NCT05718037 — Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05672966 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wuhan BravoVax Co., Ltd.
- Last refreshed: 6 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05672966.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing